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Abstract: Developmental exposure to neurotoxic chemicals presents significant health
concerns because of the vulnerability of the developing central nervous system (CNS) and
the immature brain barrier. To date, a short list of chemicals including some metals have
been identified as known developmental neurotoxicants; however, there are still numerous
chemicals that remain to be evaluated for their potential developmental neurotoxicity (DNT).
To facilitate evaluation of chemicals for DNT, the zebrafish vertebrate model system has
emerged as a promising tool. The zebrafish possesses a number of strengths as a test
species in DNT studies including an abundance of embryos developing ex utero presenting
ease in chemical dosing and microscopic assessment at all early developmental stages.
Additionally, rapid neurodevelopment via conserved molecular pathways supports the
likelihood of recapitulating neurotoxic effects observed in other vertebrates. In this review,
we describe the biological relevance of zebrafish as a complementary model for assessment
of DNT. We then focus on a metalloid and two metals that are known developmental
neurotoxicants (arsenic, methylmercury, and lead). We summarize studies in humans and
traditional vertebrate models and then detail studies defining the toxicity of these
substances using the zebrafish to support application of this model system in DNT studies.
Keywords: arsenic; development; DNT; lead; metalloids, metals; methylmercury;
neurotoxicity; zebrafish
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1. Introduction
Developmental exposure to certain chemicals are suggested as possible causes of neurodevelopmental
impairments including reduced intelligence quotient (IQ), autism spectrum disorder (ASD) and
attention deficit hyperactivity disorder (ADHD) [1–4]. The particular susceptibility of the developing
central nervous system (CNS) has been noted for decades and several publications suggest that there
might be a critical window of exposure during brain development [5–8]. It has also been discussed that
early-life stimulation via environmental stressors such as chemical exposures may trigger genetic or
epigenetic changes that modulate an organism’s biological system, which in turn leads to
neurodevelopmental alterations [7,9–11]. Thus, exposure of early-life organisms to certain chemical
compounds, especially during the critical period of development including prenatal and early postnatal
stages, can have significant adverse impacts on the process of CNS development. In addition, some
characteristics of neurodevelopmental disorders (e.g., those associated with ADHD and ASD) can
continue into adulthood, implying the adverse effects of a childhood neurodevelopmental alteration can
influence health throughout the lifespan [12,13].
To date, several chemicals including some metals and their related compounds are noted as
neurotoxicants (reviewed in [14,15]). However, currently there is insufficient evidence to prove
developmental neurotoxicity (DNT) for the majority of chemicals with only a few of them
(e.g., arsenic, methylmercury, and lead) reported as known developmental neurotoxicants (reviewed
in [14,15]). Environmental contamination of arsenic, methylmercury, and lead is widespread, resulting
in frequent human exposure raising public health concerns (reviewed in [16–20]). These toxicants are
non-biometals that do not play a role in biological systems and have been associated with
neurodevelopmental alterations in developing organisms [3,21–23].
The little progress in identifying the DNT of chemicals is in part due to the limitation of studies
using conventional in vivo models (e.g., non-human primates and rodent models), of which
experiments are laborious, time-consuming, and may not be cost-effective. To this end, the zebrafish
model system has emerged as a suitable complementary in vivo DNT test model. This model system
has been applied historically as a powerful in vivo tool for developmental biology studies with
numerous strengths as a laboratory test animal. The embryonic developmental stages of zebrafish are
well documented, which provides a guide for researchers to identify major physiological alterations
occurring during developmental toxicity assays [24]. Moreover, there is continuous progress on
uncovering the developmental processes of the CNS and blood-brain-barrier (BBB) of the
zebrafish [25–30]. Overall development of the zebrafish CNS and patterning of brain sub-regions are
completed within three days after fertilization during which neurogenesis and formation of pioneer
axons initiate (Figure 1). The rapid CNS development coupled with the general strengths of the
zebrafish model system allows screening of chemical compounds for potential DNT, resulting in the
zebrafish being an ideal complementary model for DNT studies.
In this review, the general merits and biological significance of the zebrafish as a DNT test model
are described. We then summarize DNT studies of a known metalloid and two metal neurotoxicants
(i.e., arsenic, methylmercury, and lead) in humans and traditional vertebrate models. Moreover, we
introduce research studies utilizing the zebrafish for DNT assessment of various chemicals and also
show potential of the zebrafish as an in vivo model for rapid chemical-induced DNT screening. Finally,
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we discuss progresses made in studies on the DNT of arsenic, methylmercury, and lead using the
zebrafish to support the application of this model system in DNT studies.
Figure 1. Zebrafish neurodevelopment. (a) At 72 h post fertilization (hpf) major
subdivisions of the zebrafish brain are present; Zebrafish axonal networks visualized by
acetylated α-tubulin staining (b) at 72 hpf, (c) at 96 hpf, and (d) at 120 hpf of development.
Scale bar = 100 µm. (C, cerebellum; H, hindbrain; M, midbrain; F, forebrain).

2. Zebrafish as a Model for DNT
2.1. General Strengths of the Developmental Zebrafish Model System
The zebrafish model system has long been applied in the field of developmental biology [31–35].
Over the past decade, the zebrafish has also emerged as a popular tool for investigating the
neurotoxicity of drugs and environmental chemicals [36–66]. The zebrafish presents numerous
strengths as an in vivo test model including ex utero fertilization and transparency of embryos
and early larvae, enabling microscopic observation through early developmental stages. The ex utero
embryonic development also eases the determination of doses of exposed chemicals at all embryonic
stages, providing explanation of exposure kinetics of chemicals of interest [67–70]. Moreover, the
rapid growth and high fecundity of zebrafish facilitate higher throughput toxicity testing of multiple
chemicals. In addition, a high degree of genetic similarity (≈70%) with humans allows application of
zebrafish for human disease genetic studies [71]. The fully sequenced zebrafish reference genome,
combined with the ability to use reverse genetic approaches, eases mechanistic studies on chemical
toxicity using this species. The similarity of neural development between the zebrafish and other
vertebrates also supports the application of the zebrafish as a complementary research tool to
conventional vertebrate models for DNT assays [25,28,72]. There is also biological similarity between
the zebrafish and other vertebrates in the development and function of biological barrier systems in the
developing CNS (i.e., the BBB). The BBB is one of the most effective barrier systems in vertebrates
and it is generally accepted that the BBB plays a pivotal role in the protection of the brain against
neurotoxic insults. While there are many similarities, there are also some differences between the
development of the zebrafish and mammalian brain. These similarities and differences are
discussed below.
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2.2. Comparison of Mammalian and Zebrafish CNS Development
Following fertilization in vertebrates, the newly formed embryo undergoes several cycles of rapid
cell division, during which a blastula (i.e., a single-cell organism) transforms into an embryo at the
gastrula stage (i.e., a multi-cell organism). During gastrulation, three germ layers including the
endoderm (the interior germinal layer), ectoderm (the outside germinal layer), and mesoderm are
formed. The ectoderm, specifically the neuroectoderm, gives rise to the CNS (reviewed in [25,28]),
whereas the endoderm and mesoderm are involved in the development of other organs (e.g., the kidney,
liver, and pancreas) and tissues (e.g., bone and connective tissue). The neuroectoderm specifies to the
neural plate, the origin of the CNS. The formation of the neural plate is followed by the neurulation
process, in which the neural plate folds to generate the neural tube (reviewed in [25,28]). The neural
tube eventually forms major components of the CNS including the brain, spinal cord, and nerves.
Similar to the general processes of vertebrate neurogenesis, development of the zebrafish CNS also
begins with the specification of the neuroectoderm and generation of the neural plate. At this point, the
zebrafish embryo undergoes a slightly different process from general vertebrate neurulation. Unlike
most vertebrates, which directly generate the neural tube by neural plate folding, the zebrafish converts
the neural plate to the neural keel, which then forms the neural rod and then the neural tube [28,73].
The arrangement of critical divisions of the brain proceeds during gastrulation. In the zebrafish,
gastrulation occurs from 5.25–6 to 10 h post fertilization (hpf), during which precursors of the
forebrain and other regions (i.e., the midbrain, hindbrain, and spinal cord) proceed toward the anterior
and more posterior positions, respectively [24,30]. Zebrafish primary neurons appear by
24 hpf, forming simple neuronal clusters in neuromeres (reviewed in [74]). During early
embryogenesis, there are only a few axonal tracts and commissures, but with the initiation of axonal
projections by the primary neurons complex neuro-networks throughout the body through later
developmental stages are gained (Figure 1b–d) [74–78]. The morphological development of major
organ systems nears completion at the end of embryogenesis (≈72 hpf) with the BBB present at an
earlier stage [24,29].
2.3. Blood-Brain Barrier (BBB) in the Zebrafish
The BBB is composed of endothelial cells on cerebral blood capillaries. The BBB protects the brain
from toxicants by preventing free-transport of substances. The filtering function of the BBB occurs by
endothelial cells connected through tight junctions restricting free movement of ions or solutes
(e.g., toxicants and macromolecules) between inside and outside of the barrier (reviewed in [79]). The
BBB also isolates neurotransmitters and neuroactive substances in the CNS from those in the
peripheral nervous system, hindering the interaction between the two systems (reviewed in [79–81]).
Most water soluble substances are not able to freely enter the BBB because the tight junctions that
connect nearby endothelial cells limit the movement of hydrophilic solutes through paracellular
networks [79,82]. However, substances with low molecular weight or lipophilic characteristics can
diffuse through the transmembrane relatively easy, implying that the BBB is not an absolute barrier
against neurotoxic chemicals [83,84].
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Although the BBB may play a significant role in understanding the influence of exposure to
neurotoxic substances on the developing brain, the functional mechanism and the maturation process
still remain to be elucidated. It has been a generally accepted notion that the formation of the BBB is
not complete during early developmental stages; in humans, it is not until the age of 6 months, during
which the young brain still undergoes critical development up until 2 years of age [85–87]. However,
this assumption of the immature BBB has been challenged with increasing evidence showing that the
BBB appears at very early developmental stages and that proteins involved in BBB formation and also
functional tight junctions exist in the developing brain (reviewed in [88–90]). There are several
important players involved in the BBB junctional complex activity that maintains the homeostasis of
the brain including two tight junction proteins: Claudin-5 and Zona occludens protein 1 (ZO-1) [91–96].
The genes encoding these proteins in humans (CLDN5 and TJP1, respectively) and in mice (Cldn5 and
Tjp1, respectively) are also found in zebrafish as cldn5a and cldn5b, and as tjp1a and tjp1b [97–101].
The presence of the BBB in zebrafish at early life stages became evident by Umans and
Taylor [29] when a drug transporter protein (i.e., multidrug resistance protein 1) at the BBB was
immunohistochemically visualized at 48 hpf. While the exact timing of complete maturation of
zebrafish BBB is unclear, it has been revealed that two tight junction proteins, Claudin-5 and ZO-1, in
zebrafish brain endothelial cells are expressed as early as 72 hpf [27]. As visualized by Jeong et al. [27],
the BBB of zebrafish is functional at 72 hpf as the leakage of an injected large molecular weight tracer,
rhodamine-dextran (10 kDa) was restricted in microvessels of brain parenchyma. The zebrafish BBB
may undergo further maturation to exclude small molecules after completion of embryogenesis,
as shown in Fleming et al. [102] with the inclusion of Evans blue (961 Da) and sodium fluorescein
(376 Da), restricted through 5 and 10 days after fertilization, respectively.
Due to the vulnerability of the developing CNS and limited information about the BBB function of
organisms at early life stages, a developmental exposure to environmental chemicals raises significant
concerns for potential detrimental effects to the CNS and contribution to neurodevelopmental disorders.
To date, a short list of chemicals including some metals and metalloids (e.g., arsenic, methylmercury,
and lead) are identified as known developmental neurotoxicants (reviewed in [14,15]). In the sections
below, we summarize the developmental neurotoxic effects of these toxicants as observed in humans
and in traditional in vivo vertebrate animal models. We also introduce studies on various chemicals
subjected to DNT testing using the zebrafish model. We then detail studies that have used the zebrafish
model system for DNT assessment of arsenic, methylmercury, and lead.
3. DNT of Arsenic, Methylmercury, and Lead
3.1. Arsenic
Arsenic is a metalloid element existing in nature, which can be found in an inorganic or organic
form with several oxidation states, including trivalent arsenic (arsenite) and pentavalent arsenic
(arsenate). Exposure to arsenic raises health concerns as it can damage our body by interacting with
biomolecules and produce reactive oxygen species (reviewed in [103]). Arsenic has a long history of
use as a pesticide, food preservative, and cancer chemotherapeutic agent (reviewed in [103]). Although
the application of arsenic in the production of pesticides and food preservatives has mostly
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been phased out, human exposure to arsenic still occurs because of the widespread environmental
contamination and natural presence in geological stores in some regions of the globe [18,19,104–108].
Epidemiological studies report a number of arsenic exposure cases through contaminated drinking
water supplies. Global epidemiological studies report a close relationship between early-life arsenic
exposure and intellectual/cognitive ability of school-aged children [109–112]. For example, in a recent
study conducted in the United States (US), Wasserman et al. [112] investigated the association of
arsenic exposure through drinking water at home and the IQ levels of 272 school-aged children
(mean age of 9.67-years) with the mean residence time in the current dwelling place (~7.34 years).
Researchers compared the IQ of children exposed to low levels of arsenic (arsenic concentrations in
water below 5 µg/L) to the IQ scores of those exposed to high levels of arsenic (arsenic concentrations
in water between 5–10 µg/L). In participants exposed to high levels of arsenic, there was a significant
decrease in the overall intellectual ability with about a six-point decrement in full scale IQ [112].
When tested with younger aged groups, however, the adverse effects of arsenic exposure on
children’s intellectual development becomes inconclusive [109,113]. For example, Nahar et al. [109]
and Hamadani et al. [113] examined the association of children’s IQ levels with urinary arsenic
concentrations obtained from the participants at the age of 4 and/or 5 years. In the study of
Nahar et al. [109], researchers found an association between arsenic concentration in urine and a
significant decrease in non-verbal IQ levels, but not in verbal IQ. On the other hand, Hamadani et al. [113]
found a significant negative relationship between the urinary arsenic levels and verbal as well as full
scale IQ of female children at 5 years of age.
There are also studies completed on infantile neurodevelopment in relation to prenatal arsenic
exposure. According to two recent birth cohort studies, the impact of arsenic exposure on early
neurodevelopment may not be identical in infants at different ages [114,115]. When a study was
conducted with 1-day old infants, researchers did find a negative relationship between the arsenic
levels measured in cord blood and the neurodevelopmental status of newborns when evaluated by
Brazelton Neonatal Behavioral Assessment Scale (III) [115]. However, this negative relationship did
not appear in a more recent study with neurodevelopment evaluated by the Bayley Scale of Infant
Development (II) using a cohort of 6-month old infants [114].
Rodent studies have reported reproducible results showing neurobehavioral and neurophysiological
alterations following a developmental arsenic exposure continuing over different periods of time [116–118].
In studies conducted under sub-chronic or chronic exposure conditions, rats treated with arsenite from
early gestation exhibited behavioral changes with impaired learning/memory ability [117,118]. For
instance, rats treated with 36.7 mg/L arsenite from gestation day (GD) 15 through 4 months of age
exhibited significant alterations in spontaneous locomotion and poor performance in the delayed
alternation test [117]. In addition, more recent studies with shorter exposure periods (e.g., arsenite
exposure beginning in early gestation until weaning) show molecular-level changes occurring in the rat
brain, including reduced enzymatic antioxidant activity and altered expression of neural cell adhesion
molecules [116,119]. Studies conducted in the past five years on the neurotoxic effects of arsenic
exposure with rodent models in developmental stages are summarized in Table 1.
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Table 1. A selection of studies carried out over the past five years on the neurotoxic effects of arsenic, MeHg, or Pb exposure in the zebrafish
or in vivo rodent models during developmental stages.
Substance Endpoints
Axonal/nerve
growth

Arsenic

Behavioral
alteration

In Vivo Model

Concentration a

Exposure Period b

Zebrafish

2 mM

4–48 hpf

Rat

Zebrafish
Rat

13.6 mg/L
(≈0.1 mM)
10 mg/L
(≈0.08 mM)
or above
2 mM
or above
0.1 mg/kg
(≈0.5 µM)
or above
4 mg/kg
(≈0.02 mM)

MeHg

Transcriptomic
endpoint

Behavioral
alteration

Mouse

2.6 mg/kg
(≈0.01 mM)

Key Observations c
Altered axon outgrowth in the brain and nerve growth in
the spinal cord

References
Li et al.
[120]
Luo et al.
[116]

GD0–PND21

Delayed behavioral development (reflex responses)

GD6–PND42

Altered reflex responses or learning/memory behaviors

Xi et al.
[118]

4–30 hpf

Decrease in reflexive movement frequency under
light stimulation

Li et al.
[120]

GD6–PND10

Altered expression of genes related to brain
development functional cluster in female offspring brain

Radonjic
et al. [121]

Altered expression of genes related to functional classes
of cell morphology/function, growth factor activity, or
receptor binding in pup brain

Jayashankar
et al. [122]

Altered expression of genes enriched in cell proliferation
or stress response functions in pup brain

Jayashankar
et al. [123]

for 9 weeks including
gestation period and
2 weeks post-partum
for 8 weeks including
gestation period and
2 weeks post-partum

1.5 mg/kg
(≈0.007 mM)
or above

for 11 weeks including
gestation period and
2 weeks post-partum

Zebrafish

60 µg/L
(≈0.3 µM)

48–72 hpf

Rat

0.5 mg/kg
(≈0.002 mM)

GD7–PND21

Exposure to MeHg chloride or MeHg cysteine altered
expression of genes involved in functional clusters of
immunoglobulin, metal/zinc binding, or methylation in
pup brain
Altered expression of clusters of genes involved in
apoptosis, oxidative stress response, transcriptional
elongation, or DNA repair
Altered vertical activity in 2-month old female, but not
in male rats

Glover et al.
[124]
Ho et al.
[125]
Cauli et al.
[126]
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Table 1. Cont.

Substance Endpoints

Transcriptomic
endpoint
Axonal/nerve
growth

In Vivo Model

Concentration a

Mouse

1.5 mg/kg
(≈0.007 mM)

Mouse

0.1 mM

GD8–PND21

100 ppb
(≈0.5 µM)
100 ppb
(≈0.5 µM)
5 mg/L
(≈0.02 mM)
2.84 mg/mL
(≈14 mM)
10 nM
or above
0.1 mg/L
(≈0.5 µM)
or above
0.025 mg/L
(≈0.1 µM)
or above

Zebrafish
Zebrafish

Rat
Pb
Behavioral
alteration
Zebrafish

0.2 mM
a

Exposure Period b
for 11 weeks including
gestation period and
2 weeks post-partum

Key Observations c

References

Altered open field activity in pups exposed to MeHg
chloride, but not MeHg cysteine

Glover et al.
[124]

2–16 cell stage
−72 hpf

Altered expression of genes related to signal
transduction pathway in female pup brain
Altered global expression of genes related to
neurological development, functioning, or diseases

≈2–≈36 hpf

Decreased density of axon tracts

GD0–60 days of age
in offspring

Increased locomotor activity

Kasten-Jolly
et al. [127]
Peterson
et al. [128]
Zhang et al.
[70]
Luo et al.
[129]
Molina et al.
[130]
Rice et al.
[131]

GD1–PND24
<2–24 hpf
≈6–8 to 20–30 hpf

Maternal Pb exposure did not induce anxiety-related
behavioral change in pups
Altered startling behavior in response to tapping
stimulation
Altered spontaneous movement

6–120 hpf

Altered swimming activity in response to
light stimulation
Altered swimming activity under light or dark condition

0–144 hpf

Altered spontaneous swimming activity

6–96 hpf

Chen et al.
[132]

Dou and
Zhang [133]

Concentration of substances tested on animals followed by key observation; b GD, gestational day; hpf, hours post fertilization; PND, post-natal day; c Significance of
key observations is described in comparison to that of control.
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3.2. Methylmercury
Mercury (Hg) is a common metal that is naturally present in the environment. Hg can also be
released by human activities such as gold mining or coal burning, which in turn contaminates air, soil,
and water [134]. In the aquatic environment, Hg accumulates in aquatic biota and biomagnifies
through the food chain. As a result, animals at the top of the food web (e.g., heavy seafood consumers)
tend to be exposed to relatively high levels of Hg. Similarly, seafood consumption has also been
pointed out as a primary source of human exposure to Hg [135,136]. Hg can exist in several oxidation
states including elemental (Hg0), mercurous (Hg1+), and mercuric mercury (Hg2+). The mercurous and
mercuric Hg can interact with carbon containing compounds, resulting in the formation of
methylmercury (MeHg) and ethylmercury.
Historically, health concerns of CNS exposure to Hg have mainly arisen from exposure to MeHg
(reviewed in [137,138]). Therefore, the emphasis in much research has been placed on revealing the
neurotoxicity of MeHg, especially in prenatal and early postnatal organisms. The potent neurotoxic
effect of MeHg during development is well known from the environmental disaster in Minamata,
Japan in the mid-1950s. In this early event, maternal consumption of seafood contaminated with high
levels of MeHg (i.e., umbilical cord blood level at 1 ppm or higher) resulted in the poisoning of the
fetus (reviewed in [138]). Consequently, the affected infants diagnosed with congenital Minamata
disease exhibited a variety of neurodevelopmental symptoms (e.g., mental retardation, dysarthria, and
chorea) with severe damage in the brain cortex and cerebellum (reviewed in [138]).
In later years, two important cohort studies, the Seychelles Child Development Study (SCDS) and
a study with the Faroese birth cohort, were conducted to examine the effect of prenatal MeHg exposure
on the neurodevelopment of children. Both of these studies recruited cohorts of offspring who were
maternally exposed to MeHg through high-fish diets, but showed dissimilar results. One prospective
study using the Seychelles cohort started with hair sampling of 779 pregnant women for MeHg
measurements in 1989–1990 [139]. The measured hair MeHg level, an indicator of maternal MeHg
exposure, was used for comparison with the offspring’s neurodevelopmental status evaluated by
applying age appropriate test batteries (e.g., the Bayley Scales of Infant Development and Wechsler
Intelligence Scale for Children) at 6, 19, 29, 66 and 107 months of age [139]. There are a number of
publications using the cohort of the SCDS that have followed up on the neurodevelopmental status of
the test participants (up to 17 years of age in Davidson et al. [140]); however, the clear association
between maternal MeHg exposure and neurodevelopmental alterations in the affected offspring has not
been identified [140–143].
Another study was performed with a birth cohort in the Faroe Islands that included 1022 children
born during 1986–1987 [144–147]. In studies using this birth cohort, researchers measured MeHg
levels in maternal hair and cord blood to estimate the level of prenatal exposure. Offspring were then
subjected to neurobehavioral tests (e.g., the Boston Naming Test and the California Verbal Learning
Test) at 7 and 14 years of age [144–147]. Unlike the results shown in the SCDS, children in the
Faroese Islands exposed to MeHg as a fetus exhibited neurobehavioral alterations, suggesting the
negative impact of prenatal MeHg exposure on the offspring’s neurodevelopment [144–147].
There are also studies reporting new observations that prenatal MeHg exposure may cause damage
in brain areas involved in the processing of visual information [148,149]. For example, when 102 Inuit
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children were tested at preschool age, higher plasma MeHg levels in children were associated with
altered ability of brain visual processing [148]. Similar neuropsychological alterations were also
reported in teenagers (14 years of age), suggesting that maternal MeHg exposure may have a long
lasting impact on offspring’s visual information processing capability [149].
In addition, nonhuman primate studies have been conducted on the DNT of MeHg [150].
Gunderson et al. [151,152] reported that maternal MeHg exposure of non-human primates impaired
the cognitive ability of their offspring, leading to decreased visual recognition memory in affected
infants. In Burbacher et al. [153], infant monkeys maternally exposed to MeHg exhibited altered social
behavior compared to the control monkey offspring. Long-term postnatal exposure to MeHg also
negatively impacted visual function in monkeys at older ages (≈4 years of age) [154,155].
In vivo rodent models developmentally exposed to MeHg exhibited neurobehavioral (e.g., motor
activity, startle response, learning/memory ability, or activity related with one’s motivation) and/or
physiological (e.g., brain gene expression, enzymatic activity, or neuronal cell damage)
changes [124,126,156–165]. Interestingly, the effects of developmental MeHg exposure may be
different depending on sex or age of test animals at the time of DNT evaluation. As an example, in one
study, female rat offspring maternally exposed to MeHg (0.5 mg/kg/day, from GD7 until postnatal Day
21) exhibited a decrease in vertical activity when tested at 2 months of age, while the activity of male
offspring increased at the age of 3 months [126]. In another study, Beyrouty et al. [157] observed
abnormal movement in female offspring, but not in males, when mothers were treated with MeHg
(0.5 mg/kg/day from 4 weeks before mating until GD20) in response to auditory stimulation compared
to control. Moreover, a significant decrease in monoamine oxidase enzyme activity was also detected
in the brainstem of female offspring maternally treated with a higher dose of MeHg (1 mg/kg/day),
while this change of enzymatic activity did not appear significant in male offspring [157]. Studies
conducted in the past five years on the neurotoxic effects of MeHg exposure with rodent models in
developmental stages are summarized in Table 1.
The underlying mechanisms of MeHg DNT are not yet fully understood, but may be associated
with interference of receptor activities involved in signaling pathways, oxidative stress defense
mechanism, or the differentiation of the BBB [159,162–165].
3.3. Lead
Lead (Pb) is a metallic element, which occurs naturally in the environment. Pb, with a common
oxidation state of 2+ or 4+, exists as organic Pb and inorganic Pb, with humans being exposed to both
forms. Human exposure to Pb increased extensively with its utilization in production of industrial
chemicals (e.g., as a gasoline additive and in Pb-based paint) during the 1920s–1970s. Since the
mid-1970s, the addition of Pb for fuel or paint production has been restricted in many of the developed
countries including the US because of the increasing health concerns associated with Pb exposure on
various organ systems including the CNS. However, even after the withdrawal, environmental Pb
exposure is still an ongoing concern in that exposure to low doses of Pb is reported to be associated
with neurodevelopmental alterations in children [2,3].
Neurotoxic consequences of a developmental Pb exposure was noticed as early as the 1970s by
studies conducted with subjects who were exposed to relatively high levels of Pb (e.g., a mean
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concentration of 202.1 µg Pb/g dentine) [166,167]. These early studies reported that Pb-exposed
children exhibited several features of neurodevelopmental deficits including cognitive decline,
decreased IQ score, and learning disabilities [166,167]. Later, studies with children exposed to much
lower levels of Pb also detected similar neurodevelopmental deficits [168,169]. One noticeable
example is a prospective study conducted by Bellinger et al. [168]. In this study, a cohort of
249 children was categorized into three groups according to their prenatal Pb exposure levels estimated
by measuring cord blood Pb concentration ranging from below 3 µg/dL though 10 µg/dL or above.
Bellinger et al. [168] then evaluated the Mental Development Index (of Bayley Scales of Infant
Development) of subjects included in each of the three groups at different stages of development until
2 years of age. Subjects prenatally exposed to higher levels of Pb (cord blood Pb level of
10–25 µg/dL) showed poor performance in the cognitive development test during 2 years of
development compared to those with lower cord blood Pb levels (below 10 µg/dL), suggesting a
negative impact of prenatal Pb exposure on early neurodevelopment [168].
To date, studies continue to report negative impacts of low-dose Pb exposure (i.e., blood Pb level
below 10 μg/dL) on early neurodevelopment, leading to lowered IQ, increased ADHD risk, and poor
academic achievement in children and cognitive decline in infants [2,3,170,171]. Canfield et al. [3]
measured blood Pb levels of children at age 6–60 months and then examined their IQ scores at age
3 and 5 years using the Stanford-Binet Intelligence Scale. Researchers found a linear relationship
between a 4.6-point decline in children’s IQ and every 10 μg/dL increase of blood Pb level using a
lifetime average [3]. In addition, Braun et al. [2] reported a relationship between a developmental Pb
exposure at blood Pb levels in children below 10 μg/dL and an increased risk of ADHD. In this study,
it was shown that children at the ages of 4–15 with higher levels of Pb in the blood (2–5 μg/dL) were
at a 4.5-fold increased risk for ADHD compared to those with low blood Pb levels (below the limit of
detection through 0.7 μg/dL) [2].
In addition, nonhuman primate studies have also shown the relationship between early-life Pb
exposure and behavioral alterations [172–175]. For example, in Bushnell and Bowman [172,173],
developmental Pb exposure resulted in poor performance on reversal learning tasks. In
Laughlin et al. [176], it was also reported that monkeys developmentally exposed to Pb exhibited
altered social behavior at an early age.
A number of mechanisms of Pb DNT have been proposed and while an extensive number of studies
have been conducted, the mechanisms of Pb DNT are not yet completely understood. To this end,
several in vivo rodent studies have been performed in immature brains, relating developmental
Pb exposure with alterations of cholinergic-, catecholaminergic, or glutamatergic neurotransmitter
systems [177–180]. Several studies have related developmental Pb exposure and the function of
glutamate receptor or its subtypes (e.g., N-methyl-D-aspartate (NMDA) receptor subtypes and
metabotropic glutamate receptors) [180–183]. The functional importance of glutamate receptors is
known with their involvement in excitatory signal transmission and learning/memory function [184].
Thus, the focus of many Pb DNT mechanistic studies has been on defining expression alterations of
glutamate receptors. Accordingly, some progress has been made with studies identifying increased
sensitivity to NMDA or altered expression of glutamate receptors in brain samples (e.g., the
hippocampus) following developmental Pb exposure in rat models [180–183]. Studies conducted in the
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past five years on the neurotoxic effects of Pb exposure with rodent models in developmental stages
are summarized in Table 1.
3.4. Mixtures
There are also several studies completed evaluating DNT of metal mixtures with a specific
consideration given to mixtures of arsenic, MeHg, or Pb with each other or with other metals such as
manganese and cadmium [119,185–187] or with organic chemicals such as polychlorinated biphenyls
and polybrominated diphenyl ethers (PBDEs) [126,188,189]. Combined with the increasing evidence
in recent years, it has been revealed that developmental exposure to neurotoxic chemical mixtures may
have additive or synergistic adverse effects. However, the various outcomes and complex mechanisms
of DNT induced by co-exposure to multiple chemicals still remain largely unknown.
4. DNT Studies Using the Zebrafish Model System
4.1. Application of the Zebrafish Model in Various Chemical-Induced DNT Studies
The zebrafish model has been applied in DNT research using a variety of chemical compounds
including different classes of pesticides, ethanol, PBDEs, and other emerging environmental contaminants
(e.g., nanoparticles). These studies have demonstrated DNT of various substances, among which major
findings highlighting the potential of the zebrafish model, which are introduced in this section.
Several studies have addressed zebrafish as a suitable model for testing pesticide-induced
neurotoxicity appearing in very early stages of development [45,46,49,53,57–59,64,65]. Studies on
organophosphorus pesticides, especially chlorpyrifos, indicated that developmental exposure to this
chemical induced neurobehavioral changes in the zebrafish [46,57,65]. Eddins et al. [46] examined
effects of chlorpyrifos exposure on levels of neurochemicals of zebrafish (144 hpf), showing decreased
dopamine and serotonin levels but not norepinephrine levels. Effects of a developmental chlorpyrifos
exposure or exposure to the metabolites of chlorpyrifos on acetylcholine esterase (AChE) activity were
also assessed. In Yen et al. [65], exposure to chlorpyrifos significantly decreased AChE activity of
zebrafish (120 hpf). On the other hand, in Yang et al. [64], it was the oxon metabolite of chlorpyrifos,
not chlorpyrifos, which induced a significant decrease in AChE activity (48 and 72 hpf) with alteration
of swimming activity (72 hpf) in wild-type, and growth inhibition of axons in transgenic zebrafish (72 hpf).
DNT of pyrethroids and other pesticides (e.g., cartap, fenvalerate, fipronil, thiocyclam) has also
been tested in the zebrafish model [45,49,53,58,59]. DeMicco et al. [45] observed abnormal movement
of body, which is described as “spastic movement”, in the zebrafish (96 hpf) developmentally exposed
to Type I (bifenthrin, permethrin, and resmethrin) or Type II pyrethroids (λ-cyhalothrin, cypermethrin,
and deltamethrin). Interestingly, body curvature observed in zebrafish (144 hpf) developmentally
treated by either Type I pyrethroids (bifenthrin and permethrin) or three Type II pyrethroids was
also explained as an indication of neurotoxicity, not as a result of morphological alteration. This
interpretation, both the spasms and the curvature as consequences of DNT, turned out to be rational
since registration of diazepam (a γ-aminobutyric acid [GABA]A receptor antagonist) or MS-222
(a sodium channel blocker) after deltamethrin treatment alleviated the abnormal movements and/or the
curvature [45]. In another pyrethroid study, zebrafish exposed to cypermethrin exhibited apoptotic cell
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death (96 hpf) in the CNS region (brain and spinal cord) [58]. Cypermethrin exposure also altered
activities of enzymes responsive to oxidative stress (i.e., superoxide dismutase and catalase), level of
malondialdehyde, and expression of a gene involved in DNA repair (i.e., 8-oxoguanine DNA glycosylase
(ogg1)), suggesting the neurotoxic mechanisms related to the pathways of oxidative stress production
and DNA-repair [58]. Similar effects were shown in the study of fenvalerate to which exposure
resulted in apoptosis in the brain region of embryo and larval zebrafish [49]. In this study, changes in
superoxide dismutase activity and expression of distal-less homeobox 2 (dlx2, a gene involved in
neural differentiation) as well as ogg1 were observed, implying the involvement of oxidative stress
generation and alteration of dlx2 and ogg1 related biological processes in mechanisms of
fenvalerate-induced DNT [49].
The zebrafish model has been applied for testing the developmental neurotoxic effects of exposure
to chemicals related to Parkinson’s disease, including 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP), paraquat, and rotenone [37,62]. It seems clear that MPTP induces neurobehavioral changes
and/or neuronal decrease in the developing zebrafish [37,43,62]. In Bretaud et al. [37], while paraquat
or rotenone treatment did not induce significant changes, MPTP exposure induced decreases in
swimming speed and in the number of dopaminergic neurons in the diencephalon of zebrafish at
168 hpf and 120 hpf, respectively. Being a well-defined developmental neurotoxicant, MPTP was also
used as a positive compound by Chen et al. [43] in which sodium benzoate exposure resulted in
decreased dopamine neuronal expression of tyrosine hydroxylase and dopamine transporter at 72 hpf,
and altered larval locomotive activity at 144 hpf.
There are zebrafish studies on ethanol-induced neurotoxicity, showing the effects of developmental
ethanol exposure on several neurotoxicological endpoints (e.g., altered behavior, apoptotic cell death,
decreased retino-tectal projection area) and also the underlying mechanism [38,42,48,51]. Especially,
apoptotic cell death occurring in the head area has been pronounced as one of the neurotoxic
effects caused by developmental ethanol exposure in the zebrafish [38,48,51]. For example, in
Flentke et al. [48], ethanol toxicity was investigated in regard to the association between ethanol
exposure and fetal alcohol spectrum disorders. Flentke et al. [48] showed that ethanol exposure for 3 h
resulted in apoptotic death of neural crest cells related to the calcium calmodulin-dependent protein
kinase II signaling pathway.
Zebrafish studies have revealed the neurotoxic effects of exposure to PBDEs (e.g., DE-71, BDE-47,
BDE-49), showing alteration in neurobehavior, genetic expression, cholinergic system and/or axonal
growth [39–41,52]. As an example, in Chen et al. [39], zebrafish (120 hpf) developmentally exposed to
DE-71 exhibited altered locomotor movement, increased AChE activity, and decreased expression of
nervous system genes (myelin basic protein, α1-tubulin, and sonic hedgehog a). Parental exposure to
DE-71 (for 150 days) also induced changes in neurobehavior, CNS gene expression (myelin basic
protein, synapsin IIa, α1-tubulin), and the cholinergic system but with decreased AChE activity in F1
offspring at 96 hpf [40].
As shown in the research above, the zebrafish has a potential to be applied for testing DNT of a
broad range of chemicals. However, a limited number of zebrafish studies have been conducted on
influences of exposure to other substances (e.g., TCDD, cadmium, nanoparticles, and valproate) on
neurobehavior or neurogenesis in the developmentally exposed zebrafish [42,44,50,54,63,66]. To this
end, there has been a need to develop the strengths and further the application of the zebrafish as a
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model organism for DNT testing. Studies have suggested endpoints which can serve as indicators in
DNT screening of a variety of chemicals, which are described in the below section.
4.2. The Zebrafish as a Potential Tool for Chemical-Induced DNT Screening
The zebrafish model allows screening of multiple chemical DNT within a few days through
examination of cellular (apoptosis) or specific neuronal proliferation (neuronal development or survival)
appearing in the brain region by utilizing simple staining methods such as acridine orange (AO)
staining or immunostaining [60,61]. For example, Ton et al. [61] suggested the zebrafish as a screening
tool for DNT assessment, showing that measurement of cell death in the brain can be a useful endpoint
using the zebrafish in the early life stage (96 hpf). Zebrafish were treated with five test chemicals (e.g.,
atrazine, 2,4-D, DDT, dieldrin, and nonylphenol), one teratogen (TCDD), or one negative compound
for neurotoxicity (malathion) and then axonal tracts, catecholaminergic neurons, and apoptotic cell
death occurring in the brain region visualized [61]. DNT was differentiated from teratogenic effects by
obtaining the teratogenic index of each chemical. The results specified 2,4-D, dieldrin, and
nonylphenol as developmental neurotoxicants among the seven chemicals tested [61].
Fan et al. [47] and Cowden et al. [42] suggested the examination of the quantitative expression of
selected genes or the retino-tectal projection area as potential DNT endpoints. The relevance of these
endpoints was proven using ethanol and/or valproate as model neurotoxicants. Fan et al. [47] provided
gene expression profiles of ten nervous system genes (e.g., glial fibrillary acidic protein, myelin basic
protein, nestin, synapsin IIa) with control genes (ribosomal protein L13A and elongation factor1 alpha)
during zebrafish development (≈6 days), so that this information can be used for future DNT screening.
Neurobehavioral alterations are a popular neurotoxicological endpoint in DNT studies using the
zebrafish. With the small size, transparency, and ex vivo embryonic development of the zebrafish, live
tracking of zebrafish behaviors using video recording tools is available from the early embryonic
stages. A recent study by Kalueff et al. [190] further defined major behaviors of zebrafish to aid in the
interpretation of zebrafish behavioral changes as phenotypes of neurological alterations. In the field of
DNT research, the zebrafish neurobehavioral changes observed as endpoints can be grossly divided
into three categories: spontaneous movement, touch-responsive movement, and locomotor activity
induced without touch stimulation. These endpoints have been the basis for the development of
methods for screening chemical-induced DNT in recent studies [42,55,56]. For example, as an attempt
to provide a method for DNT screening using zebrafish, Selderslaghs et al. [56] examined behaviors of
embryos (spontaneous movement) and larvae (swimming activity). These neurobehavioral endpoints
were observed following exposure to seven chemicals with known DNT (e.g., acrylamide, bisphenol A,
chlorpromazine, or MeHg) or three negative substances (e.g., acetaminophen, omeprazole, or saccharin).
These results were then compared to the existing literature on the DNT of these chemicals [56]. Test
results using all chemicals but omeprazole corresponded to existing animal data, showing the potential
of the zebrafish in early life stages as a tool for screening chemical-induced DNT [56].
Overall with the recent gains in knowledge on zebrafish neurobehavior and transcriptional
regulation, behavioral assays and transcriptional assessments provide comparable DNT data to
traditional rodent model studies. Furthermore, various strengths of the zebrafish are being utilized to
further the understanding of DNT at endpoints that are not as easily assessed in rodent models. For
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example, the ex vivo embryonic development allows microscopic examination of developing axons
immediately after fertilization, serving as a valuable indicator of DNT which is not as easily assessed
in other vertebrate model systems.
4.3. DNT Studies of Arsenic, Methylmercury, or Lead Using the Zebrafish
The zebrafish has been utilized in several studies on the DNT of arsenic, MeHg, and Pb (Table 1).
In these studies, the neurotoxic consequences of developmental metal exposures and/or the underlying
mechanisms of metal DNT have been investigated from various angles (e.g., axonal growth inhibition,
transcriptomic alterations, or neurobehavioral changes). In this section, we review the progress made
in DNT studies on the metalloid arsenic and the two metals MeHg and Pb using the zebrafish as a test
organism to support further studies of DNT using this model system. As an effort to differentiate
developmental toxicity from DNT, overt signs of toxicity such as altered hatchability of embryo,
lethality, or gross morphological (e.g., craniofacial alteration) or histological (e.g., organ edema)
changes are excluded from the review unless the neurotoxic origin of those effects are clarified.
There are a few studies describing the effects or mechanisms of neurotoxicity associated with a
developmental exposure to arsenic. In a study by Li et al. [120], zebrafish embryos were exposed to
either a control treatment or various concentrations of sodium arsenite from 4 hpf. To investigate the
effects of arsenite exposure on early neurodevelopment, the zebrafish embryos were subjected to either
simple microscopic observations at 30 hpf or immunostaining at 48 hpf [120]. The former experiment
was conducted to observe the reflexive actions of embryos in response to light stimulation, revealing
that the frequency of motions made by embryos developmentally treated with 2 or 5 mM arsenite
decreased significantly compared to the control zebrafish [120]. As the zebrafish in very early stages
of development has a relatively simple neuronal network, the observation of the reflexive movement
may reflect the altered neuronal function derived from arsenite exposure, not the secondary outcome of
non-DNT (e.g., growth retardation). In the immunostaining experiment, axonal tracts of zebrafish
embryos were visualized using acetylated α-tubulin (α-AT) antibody and showed altered growth
patterns of axons in the brain and spinal cord of zebrafish exposed to 2 mM of arsenite compared
to those in the control treatment [120]. Furthermore, researchers also found that exposure to 2 mM
arsenite induced changes in patterns of cell proliferation, cell death, and DNA methylation in
developing zebrafish at 24 and/or 48 hpf using various methods including proliferating cell nuclear
antigen (PCNA) labeling, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
assay, and 5-methylcytidine labeling [120]. Based on these observations, it might be reasonable to
assume that arsenite DNT is related to the altered biological processes strictly regulated by proper cell
proliferation, apoptosis, or DNA methylation during normal embryonic development. To generalize
this assumption, however, additional investigations into the molecular mechanism of arsenite DNT
need to be performed to clarify that the effects observed in the zebrafish are the consequences of DNT
and not of teratogenicity. A follow-up study by Li et al. [191] investigated the mechanisms of arsenic
DNT with a focus on the activity of zebrafish Dvr1, which is involved in axis formation (known as
growth differentiation factor 1 (GDF1) in mammals). In this study, quantitative polymerase chain
reaction (qPCR) and whole mount in situ hybridization techniques were utilized to detect the levels of
Dvr1 expression in the developing zebrafish. The results of this study showed a decrease in Dvr1
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expression in 2 mM sodium arsenite treated embryos compared to those in the control group at 6 hpf in
both of the experiments [191]. To further investigate the association between Dvr1 function and early
development of the zebrafish nervous system, researchers injected a Dvr1 morpholino (MO) with or
without plasmids encoding Dvr1 homolog (e.g., mouse GDF1) [191]. By performing this simple MO
injection into the embryo, expression of a specific gene of interest can be silenced in the zebrafish.
The generated Dvr1 morphants were then subjected to α-AT staining at 48 hpf and showed impaired
neural development in the brain, trunk, and tail compared to embryos in the control treatment
(i.e., not genetically manipulated embryos) [191]. In the same immunostaining experiment using
embryos co-treated with Dvr1 MO and plasmids, the expression of mouse GDF1 alleviated the
neurodevelopmental effects of Dvr1 knockdown, suggesting the involvement of Dvr1 in the mechanism
of arsenic DNT in the zebrafish [191].
Long et al. [192] identified the expression of abcc5 (ATP-binding cassette transporter), which plays
a role in cellular signaling and protection from xenobiotics, in the zebrafish embryo with or without an
exposure to heavy metals including arsenic, mercury, and Pb. Firstly, Long et al. [192] characterized
quantitative and spatial expression of abcc5 by using qPCR and whole mount in situ hybridization,
revealing that abcc5 was expressed in the lens and brain during embryogenesis (24, 48, and 72 hpf).
The level of abcc5 expression was then evaluated in embryos treated with different concentrations of
metals, including sodium arsenate (100 µM), Hg chloride (0.5 µM), or Pb nitrate (50 µM) [192]. qPCR
results indicated that each metal exposure (through 24 to 48 hpf) resulted in a significant increase in
quantitative abcc5 expression [192]. The pattern of abcc5 expression observed without metal exposure
implies that this gene may have a role in distinctive regions including the brain during embryogenesis.
Although it needs to be further elucidated, considering the function of abcc5 is to transport cGMP in
signal transduction, one can speculate that expression alterations of abcc5 induced by metal exposure
may interfere with important biological processes such as neurodevelopment.
The zebrafish model system was also applied to investigate MeHg DNT. Hassan et al. [193]
observed a significant reduction of cellular proliferation occurring in the neural tube of zebrafish
developmentally exposed to 10, 50, or 80 µg/L (≈0.4 µM) MeHg at 30 hpf using PCNA staining.
Cuello et al. [194] investigated the effects of MeHg exposure on zebrafish development at the protein
level using iTRAQ (isobaric tags for relative and absolute quantification). Altered expression of
proteins involved in calcium binding (e.g., parvalbumin-2 and parvalbumin 9, and parvalbumin
isoform 1d) was observed in the zebrafish treated with 25 µg/L (≈0.1 µM) MeHg from 72 to 144 hpf,
suggesting the disturbance of calcium homeostasis as an important mechanism of MeHg toxicity. More
recently, Ho et al. [125] treated embryos with 60 µg/L (≈0.3 µM) MeHg from 48 to 72 hpf and then
conducted microarray analysis, which enables global detection of gene expression changes in the
zebrafish. Researchers then conducted a whole mount in situ hybridization with 88 genes that showed
substantial expression changes in the microarray analysis and confirmed expression alterations of 60 of
the 88 genes [125]. The data from the in situ hybridization experiments also allowed further grouping
of genes according to their expression patterns shown in different tissues. In this analysis, 24 of the
88 genes had specific expression alterations in the brain region [125]. These 24 genes expressed in
the brain were involved in a variety of biological activities including transcriptional regulation,
development, and transport processes, implying possible biological disturbances in the zebrafish brain
affected by developmental MeHg exposure [125]. The information obtained from this transcriptomic
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analysis is valuable since there is a lack of basic data about potential molecular targets of MeHg
neurotoxicity. Thus, this data can assist in identifying targets for later in-depth studies using the
zebrafish to further define the molecular mechanisms of MeHg DNT toxicity.
Several Pb DNT studies have been carried out using the zebrafish, presenting various signs of
neurodevelopmental alterations in Pb exposed subjects (reviewed in [195]). Low concentrations tested
in the Pb exposure studies described below show that the zebrafish is indeed a very sensitive in vivo
test model for DNT assessment. For example, Peterson et al. [128] evaluated global gene expression
changes in developing zebrafish in response to a low-dose Pb exposure. Microarray analysis was
performed with embryos treated with 100 ppb (≈0.5 µM) Pb through the end of embryogenesis,
resulting in significant expression alterations of 55 genes engaged in processes related to nervous
system development/functioning and neurological diseases [128]. Western blot analysis revealed
significant changes in expression of several target proteins including metallothionein-2, FRY-like, and
reelin [128]. The results of this study are noteworthy in revealing that a low-dose of Pb was sufficient
to induce expression alterations of genes/proteins involved in the zebrafish nervous system. In addition,
it is also important to note that the alterations detected at 72 hpf were not present at 120 hpf, implying
that the effects of a developmental Pb exposure might be time point specific. It is yet unclear whether
the expression alterations of nervous system genes observed at 72 hpf are reflective of transient effects
of Pb exposure or not. To answer this question, further analyses of global changes of gene expression
appearing at stages earlier than 72 hpf and later than 120 hpf need to be performed.
In a follow-up study, Peterson et al. [196] assessed the expression of zebrafish reln (equivalent to
human reelin that is known to be involved in neuronal development and diseases). Zebrafish embryos
were exposed to up to 100 ppb Pb acetate shortly after fertilization through 24–96 hpf, and then
subjected to whole mount in situ hybridization or qPCR analysis to evaluate expression alteration of
zebrafish reln [196]. In the in situ hybridization experiment, expression of reln was noticeable in the
CNS region beginning at 24 hpf, while no spatial expression alterations were observed in response to
the Pb exposure. A significant decrease in reln expression occurred only in embryos treated with
100 ppb Pb at 60 hpf, without significant changes in brain morphology or brain cell apoptosis.
These findings suggest a time point specific role of this gene that might be involved in neurotoxic
mechanisms other than brain morphogenesis [196]. Considering the absence of apoptotic cell death in
the brain, which is one of the frequently used indicators of neurotoxicity in zebrafish studies, focus of
future studies needs to be placed on different mechanisms of neurotoxicity.
In an additional follow-up study, the effect of Pb exposure on axonal growth in the developing
zebrafish was studied following exposure to 100 ppb Pb acetate at several time points between
18–36 hpf by α-AT staining and showed a significant decrease in axonal density in Pb exposed
embryos at 18, 20, or 24 hpf [70]. The genetic mechanisms underlying this Pb-induced axonal density
decrease were investigated by measuring quantitative expression of genes involved in axon guidance in
embryos exposed to 100 ppb Pb through 14–36 hpf. The qPCR analysis revealed that expression of
sonic hedgehog a and ephrin type-A receptor 4b were significantly down-regulated at 14 and 16 hpf,
respectively [70]. On the other hand, netrin2 expression increased significantly at 30 and 36 hpf,
suggesting the involvement of netrin2 in regulating axonal growth in response to Pb neurotoxicity at
early developmental stages [70].
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Recently Wirbisky et al. [69] investigated the effects of Pb acetate exposure (up to 100 ppb, up to
72 hpf) on the GABAergic system of embryonic zebrafish using qPCR and High Performance Liquid
Chromatography (HPLC). In the qPCR analysis, Pb treated embryos exhibited time point specific
expression alterations of genes involved in GABA production (gad2, gad1b), transport
(gat-1, gat-3, vgat), and GABA receptors (gabra1, gabbr1a) throughout embryogenesis [69]. GABA
measurement by HPLC revealed that embryonic Pb exposure also induced fluctuation of GABA levels
with an increase in GABA at 48 hpf and a decrease in GABA at 72 hpf [69]. These results suggest that
Pb exposure interferes with the GABAergic system in the zebrafish during embryonic developmental
stages with different patterns of genetic expression and GABA level fluctuations. In regards to the
function of GABA which can be either excitatory or inhibitory at different embryonic developmental
stages, future observations at narrower ranges of developmental time points may explain the
importance of the GABAergic system as a mechanism of Pb-induced DNT.
Developmental Pb exposure also causes neurobehavioral changes in the zebrafish. In Rice et al. [131],
embryos were treated with up to 30 nM of Pb chloride through 24 hpf and then subjected to a
neurobehavioral test at 168 hpf. The behavioral changes of the zebrafish were evaluated on several
parameters reflecting altered movement in response to different frequencies of tapping stimulation
(i.e., one tap/s or four taps/s), showing that zebrafish developmentally treated with 30 nM of Pb
exhibited altered responses under both the one and four taps/second frequency stimulation [131].
Rice et al. [131] also provided a probable mechanistic interpretation of the behavioral changes
including altered sensitivity of mechanosensory neuromasts, function of neurons involved in signal
integration, or neurotransmitter signaling, albeit inclusive. In another study Chen et al. [132] treated
zebrafish with up to 1 mg/L (≈5 µM) Pb acetate from 6–8 hpf and monitored spontaneous movement
from 20 until 30 hpf, showing that spontaneous activity of embryos exposed to 1 mg/L of Pb
significantly decreased at most of the tested time points. Chen et al. [132] also examined behavioral
changes of zebrafish developmentally treated with lower concentrations of Pb acetate (up to 0.1 mg/L
(~0.5 µM)) starting from 6 hpf until the time of evaluation. In the test conducted under constant light
or dark condition at 120 hpf, zebrafish developmentally exposed to 0.1 mg/L Pb showed a significant
decrease and increase in mean swimming speed under light and dark condition, respectively [132].
The mechanisms of Pb DNT causing the inconsistent change of larval swimming activity as well as the
alteration of spontaneous movement are largely unknown. Considering the sensitivity of the zebrafish
embryo and larva, further elucidation may be necessary to discriminate the behavioral alteration
caused by different experimental conditions from the Pb-induced neurobehavioral effects. Taken
together, the Pb DNT studies using the zebrafish model have shown the neurotoxic effects of a
low-dose Pb exposure at specific time points. Information about molecular targets of Pb DNT in the
zebrafish allows further investigation of mechanisms involved in Pb-induced DNT. Future studies on
behavioral phenotypes and underlying molecular mechanisms at expanded developmental time points
or with lower doses of Pb will aid in the understanding of Pb DNT in the zebrafish.
5. Conclusions
The zebrafish has traditionally been a popular model in the field of developmental biology with
current expansion into all areas of biological research. The zebrafish presents a number of strengths
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as an in vivo laboratory model including the use as a complementary vertebrate model for DNT
assessment. Furthermore, the application of the zebrafish as a complementary model in DNT studies is
supported by published studies investigating the DNT of the known neurotoxicants arsenic, MeHg, and
Pb. To facilitate the application of the zebrafish model in DNT testing, further studies need to be
conducted on exposure kinetics of various substances to determine exposure doses per embryo or larva.
A few studies have started to include this analysis (e.g., [69,70]), but more work is needed in this area
to understand dose and exposure kinetics. In addition, chorionation or dechorionation status at
the time of chemical exposure may also affect the degree of chemical absorption by the embryo.
Additionally, there is a need for validation of existing endpoints to distinguish DNT from
developmental toxicity (e.g., differentiation of behavior from neurobehavior) and for the development
of novel markers which can be used as direct indicators of DNT in the zebrafish. Overall, with future
investigations, the use of the zebrafish model system will assist in the screening of developmental
neurotoxicants and ultimately facilitate our understanding of DNT mechanisms.
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